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Summary
Background: Randomized trials have shown that long-term mortality rates are similar
between patients with multivessel coronary artery disease (CAD) treated by percu-
taneous coronary intervention (PCI) and by coronary artery bypass graft (CABG).
However, there are scant data regarding more than 10 years long-term follow-up in
Asian populations. Therefore, we performed a pooled analysis of our observational
data evaluating long-term outcomes of PCI as compared with CABG in patients with
multivessel disease among a Japanese population.
Methods and results: We enrolled 1364 patients, of whom 225 (16.5%) and 1139
(83.5%) underwent PCI and CABG, respectively. During follow-up (12.8± 3.4 years),
377 patients died (cardiac death, 125; cardiovascular death, 177) and 322 underwent
revascularization. We predicted the probability of undergoing PCI using propensity
analysis. After adjusting for baseline variables including propensity score, PCI and
CABG did not differ in terms of all-cause (hazard ratio (HR) 1.12; 95% conﬁdence
interval (CI) 0.72—1.73; p = 0.62), cardiac (HR 0.62; 95%CI 0.32—1.23; p = 0.17), and
cardiovascular mortality (HR 0.83; 95%CI 0.45—1.52; p = 0.54). However, the inci-
dence of revascularization was signiﬁcantly higher in the PCI group than in the CABG
group (HR 0.20; 95%CI 0.15—0.28; p < 0.0001).
Conclusion: Although PCI was associated with a signiﬁcantly higher risk of revascu-
larization than CABG, long-term mortality rates did not signiﬁcantly differ between
the two procedures in this oriental population.
© 2008 Japanese College of Cardiology. Published by Elsevier Ireland Ltd. All rights
reserved.
∗ Corresponding author. Tel.: +81 3 5802 1056; fax: +81 3 5689 0627.
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ntroduction
andomized trials have shown that long-term mor-
ality rates are similar between patients with
ultivessel coronary artery disease (CAD) treated
y percutaneous coronary intervention (PCI) and
y coronary artery bypass graft (CABG) [1—6]. Fur-
hermore, several observational studies indicate
hat long-term survival after CABG is not abso-
utely superior to that after PCI [7—12]. However,
ll of these studies proceeded in western coun-
ries with limited follow-up periods. Furthermore,
hether CABG is associated with a lower long-term
>10 years) mortality rate relative to PCI in ori-
ntal patients remains unknown. We investigated
ong-term outcomes after revascularization using
bservational data from patients with multivessel
isease among a Japanese population.
ethods
atients and data collection
e examined consecutive Japanese patients with
ultiple vessel disease who underwent PCI or iso-
ated CABG at Juntendo University Hospital, Tokyo,
apan, between January 1984 and December 1992.
atients with a history of CABG who also required
alve surgery, who died during the procedure or
ho had already been diagnosed with a fatal
alignancy were excluded. Baseline data includ-
ng patients’ age, gender, body mass index (BMI),
istory of myocardial infarction (MI), presence or
bsence of atrial ﬁbrillation, currently undergoing
ialysis, hypertension, hypercholesterolemia, dia-
etes mellitus, smoking history, family history of
AD, presence of acute coronary syndrome (ACS)
ncluding unstable angina or acute MI, number
f diseased vessels, target vessel, left ventricu-
ar ejection fraction (LVEF), and date of procedure
ere prospectively recorded in the database of
ur institution. Outcome data, including death and
ubsequent revascularization, were collected until
eptember 2000. The medical records of patients
ho died or who were treated at our hospital were
nalyzed. When patients were admitted to or fol-
owed up at other hospitals or clinics, details of
evascularization (PCI or CABG) and the cause of
eath were obtained from these institutions. Mor-
ality data were categorized as all-cause death,
ardiac death (including death from CAD, cardio-
enic shock, and sudden death), and cardiovascular
eath (including cardiac death, death from aor-
ic disease and stroke). Data regarding coronary
r
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isk factors were evaluated in each patient using
he following criteria: hypertension deﬁned as sys-
olic blood pressure ≥140mmHg, diastolic blood
ressure ≥90mmHg, or currently taking antihyper-
ensive medications; hypercholesterolemia deﬁned
s serum total cholesterol ≥220mg/dL or currently
aking cholesterol-lowering drugs; diabetes melli-
us deﬁned as fasting plasma glucose ≥140mg/dL
r currently taking anti-diabetic medication (oral
ypoglycemic drugs or insulin injections). A cur-
ent smoker was deﬁned as a person who smoked
igarettes at the time of procedure or who had quit
moking within 1 year before the procedure. Atrial
brillation was deﬁned as persistent or permanent
trial ﬁbrillation at the time of the procedure.
atients were separated into groups according to
hether they underwent revascularization by PCI
r by CABG.
tatistical analysis
ontinuous variables are expressed as means± S.D.
nd were compared using Student’s t-test or
ann—Whitney U-test. Categorical data are dis-
layed as frequencies and percentages and com-
ared using the 2-test or Fisher’s exact test. We
pplied Kaplan—Meier estimations and Cox propor-
ional hazards models for unadjusted and adjusted
urvival analyses, respectively. We applied propen-
ity analysis to adjust variables that would have
een related to the decision regarding revascu-
arization procedure [11,13,14] and to identify
atients with similar probabilities of undergoing
ABG based on observed clinical characteristics.
ariables included in the multivariate logistic
egression analysis were: age, gender, BMI, diabetes
ellitus, hypertension, hypercholesterolemia, cur-
ent smoker, family history of CAD, history of MI,
ialysis, atrial ﬁbrillation, presence of ACS, 3 ves-
el disease, left anterior descending (LAD) lesion,
eft main trunk (LMT) lesion, LVEF, procedure date
before or after median procedure date). We then
alculated the propensity score for each patient
rom the results of this multivariate logistic regres-
ion analysis. A higher propensity score indicated a
igher probability of undergoing CABG at baseline.
he propensity scores were entered into the Cox
roportional hazard model as continuous variables
long with the baseline covariates included in the
ropensity score model (age, gender, BMI, diabetes
ellitus, hypertension, hypercholesterolemia, cur-ent smoker, family history of CAD, prior history
f MI, renal insufﬁciency, atrial ﬁbrillation, and
ovariates associated with revascularization pro-
edure, namely presence of ACS, LVEF, 3 vessel
isease, LAD lesion, LMT lesion, and procedure
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date. Additionally, subgroup analyses which were
limited to patients with ACS, diabetes mellitus,
and 3 vessel disease or LMT lesion were car-
ried out. Adjusted survival curves were generated
using this Cox proportional hazard model in con-
junction with other described methods [15,16].
Furthermore, patients who underwent subsequent
revascularization were divided into four groups: ini-
tial PCI followed by another PCI (PCI then PCI),
initial PCI followed by CABG (PCI then CABG), initial
CABG followed by PCI (CABG then PCI), and initial
CABG followed by another CABG (CABG then CABG).
We also constructed additional survival curves for
all-cause death for these four groups. p values of
<0.05 were considered signiﬁcant. All data were
analyzed using Dr. SPSS II for Windows (SPSS Inc.,
Chicago, IL, USA).
Results
Baseline characteristics
Baseline characteristics and clinical events during
follow-up (median, 12.8± 3.4 years) were collected
for all patients. Of the 1364 enrolled patients,
225 (16.5%) and 1139 (83.5%) underwent initial PCI
and CABG, respectively. Table 1 shows the baseline
characteristics of the groups. Patients who under-
went initial CABG had signiﬁcantly more severe
CAD than those who underwent initial PCI. How-
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Table 1 Baseline characteristics
PCI N = 225
Age (years) 61.4± 9.5
Male gender (%) 187 (83.1)
BMI (kg/m2) 23.5± 2.8
Risk factors
Diabetes mellitus (%) 71 (31.6)
Hypertension (%) 155 (68.9)
Hyperlipidemia (%) 137 (60.8)
Smoker (%) 158 (70.2)
Family history of CAD (%) 73 (32.4)
Prior MI (%) 65 (28.9)
Atrial ﬁbrillation (%) 25 (11.1)
Dialysis (%) 12 (5.3)
Procedure
ACS (%) 66 (29.3)
Vessel disease 2.24± 0.43
3-Vessel disease 53 (23.6)
LMT lesion (%) 1 (0.4)
LAD lesion (%) 105 (46.7)
LVEF % 65.8± 12.6
Procedure after median date 131 (58.2)
BMI, body mass index; CAD, coronary artery disease; ACS, acute c
trunk; LAD, left anterior descending; PCI, percutaneous coronary inT. Kasai et al.
ver, more of the patients who underwent initial
CI were hypertensive, on dialysis, had ACS, and
ere revascularized more recently (after 3 March
989). None of the other variables signiﬁcantly dif-
ered between the two groups. None of the patients
ho underwent PCI with balloon angioplasty were
mplanted with stents and 590 (51.8%) of those who
nderwent CABG received internal mammary artery
rafts.
ropensity score analysis
able 2 shows that the independent predictors of
decision to apply PCI or CABG in the propensity
core analysis included: age; presence or absence
f hypertension, ACS, history of MI, LMT lesions
nd LAD vessel disease (2 or 3 vessel), LVEF, and
rocedure date (before or after 3 March 1989).
he adequacy of the propensity score was con-
rmed since the area under the receiver operating
haracteristics (ROC) curve was 0.91, indicating
xcellent discrimination. A higher propensity score
n the present study indicated an increased like-
ihood of undergoing CABG. The mean propensity
cores of patients who underwent PCI or CABG
ere 0.477± 0.312 and 0.908± 0.145, respectively.
he ability of the propensity score to adjust for
aseline covariates was evaluated by testing for
ifferences in these covariates within quartiles of
he propensity score. We found that the values of
mportant variables associated with a decision to
CABG N = 1139 p-Value
59.4± 8.7 0.02
954 (83.8) 0.81
23.7± 3.0 0.38
435 (38.2) 0.052
637 (55.9) <0.0001
737 (64.3) 0.28
816 (71.6) 0.67
343 (30.1) 0.49
620 (54.4) <0.0001
174 (15.3) 0.11
27 (2.4) 0.015
181 (15.9) <0.0001
2.74± 0.44 <0.0001
842 (73.9) <0.0001
233 (20.5) <0.0001
998 (87.6) <0.0001
62.1± 13.8 <0.0001
520 (45.7) 0.001
oronary syndrome; MI, myocardial infarction; LMT, left main
tervention; LVEF, left ventricular ejection fraction.
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Table 2 Independent predictors of selection for
CABG
Predictors OR (95%CI) p
Age 0.96 (0.94—0.98) 0.001
Hypertension 0.65 (0.43—0.97) 0.036
Prior MI 2.20 (1.40—3.45) 0.001
Presence of ACS 0.46 (0.28—0.77) 0.003
3-Vessel disease 7.61 (5.02—11.5) <0.0001
LMT lesion 105.9 (14.0—800.8) <0.0001
LAD lesion 17.2 (11.0—26.9) 0.0001
LVEF 0.99 (0.97—1.00) 0.05
Procedure after
median datea
0.64 (0.43—6.94) 0.022
CABG, coronary artery bypass graft; OR, odds ratio; MI,
myocardial infarction; ACS, acute coronary syndrome; LMT,
s
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Figure 1 Survival curves (all-cause death) of patients
after PCI and CABG. Upper panel shows unadjusted cumu-
lative survival curve and lower panel shows adjusted
cumulative survival curve. Both curves show no sig-
niﬁcant difference among groups. PCI, percutaneous
c
g
D
O
f
t
a
H
wleft main trunk; LAD, left anterior descending; LVEF, left ven-
tricular ejection fraction.
a Median date, 3 March 1989.
elect a revascularization procedure did not signiﬁ-
antly differ between the PCI and the CABG groups.
djusted analyses of mortality and
evascularization
f the 377 patients who died during follow-up, 125
nd 177 were due to cardiac and cardiovascular
auses, respectively. A total of 322 patients under-
ent subsequent revascularization. Adjustments
or baseline covariates using the Cox proportional
azard model showed that the risk for long-term all-
ause mortality did not signiﬁcantly differ between
CI and CABG (HR 1.12; 95%CI 0.72—1.73; p = 0.62)
Fig. 1). Risk for cardiac (HR 0.62; 95%CI 0.32—1.23;
= 0.17; Fig. 2) and cardiovascular (HR 0.83; 95%CI
.45—1.52; p = 0.54) (Fig. 3) mortality also did
ot signiﬁcantly differ. However, the adjusted risk
f subsequent revascularization was signiﬁcantly
igher in the PCI, than in the CABG group (HR
.20; 95%CI 0.15—0.28, p < 0.0001) (Fig. 4). Table 3
ummarizes the incidence of death and subsequent
evascularization in each group and the hazard
atios. The results of subgroup analyses, which were
imited to patients with ACS, diabetes mellitus,
nd 3 vessel disease or LMT lesion, are shown in
able 4. Of the 322 patients who underwent subse-
uent revascularization (either PCI or CABG), 32.4%
nd 15.2% of the PCI group underwent repeated
CI or subsequent CABG, respectively, whereas
7.5% and 1.4% of the CABG group underwent
ubsequent PCI or repeated CABG, respectively.
ig. 5 shows the cumulative survival curves of
hese four groups. All-cause, cardiac, and cardio-
ascular mortality rates did not signiﬁcantly differ
mong them.
P
d
f
t
foronary intervention; CABG, coronary artery bypass
raft.
iscussion
ur observational study demonstrated that CABG
or patients with multivessel CAD offered no long-
erm (>10 years) advantage over PCI in terms of
ll-cause, cardiac, and cardiovascular mortality.
owever, the risk for subsequent revascularization
as signiﬁcantly higher among patients undergoing
CI. This is the ﬁrst study to provide such evi-
ence in an oriental population over a long-term
ollow-up (>10 years), and it is compatible with
he results of randomized control studies of shorter
ollow-up periods in western countries [1—6]. Our
190 T. Kasai et al.
Table 3 Adjusted HR of CABG for mortality and revascularization rates
Incidence n (%) Adjusted analysis
PCI CABG HR (95%CI) p-Value
Death from all causes 33 (14.7) 344 (30.2) 1.12 (0.72—1.73) 0.62
Cardiac death 17 (7.6) 108 (9.5) 0.62 (0.32—1.23) 0.17
Cardiovascular death 19 (8.4) 158 (13.9) 0.83 (0.45—1.52) 0.54
Revascularization 107 (47.6) 215 (18.9) 0.20 (0.15—0.28) <0.0001
PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; HR, hazard ratio; CI, conﬁdence interval. Adjustment
analysis included covariates: age, gender, body mass index (BMI), diabetes mellitus, hypertension, dyslipidemia, smoker, family
history of coronary artery disease (CAD), presentation of acute coronary syndrome (ACS), prior history of myocardial infarction
(MI), atrial ﬁbrillation, dialysis, left ventricular ejection fraction (LVEF), vessel disease, left anterior descending (LAD) lesion, left
main trunk (LMT) lesion, procedure after median date, and propensity score.
Figure 2 Survival curves (cardiac death) of patients
after PCI and CABG. Upper panel shows unadjusted cumu-
lative survival curve and lower panel shows adjusted
cumulative survival curve. Both curves show no sig-
niﬁcant difference among groups. PCI, percutaneous
coronary intervention; CABG, coronary artery bypass
graft.
Figure 3 Survival curves (cardiovascular death) of
patients after PCI and CABG. Upper panel shows unad-
justed cumulative survival curve and lower panel shows
adjusted cumulative survival curve. Both curves show no
signiﬁcant difference among groups. PCI, percutaneous
coronary intervention; CABG, coronary artery bypass
graft.
PCIvs.
CABG
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Table 4 HR of CABG for mortality and revascularization in the subgroup analysis
All-cause death Cardiac death
CABG PCI HR, 95%CI p CABG PCI HR, 95%CI p
ACS 66/181 (19.7) 13/66 (36.5) 0.79, 0.33—1.85 0.58 19/181 (10.5) 9/66 (13.6) 0.20, 0.06—0.68 0.01
Non-ACS 278/958 (25.9) 20/159 (12.6) 1.27, 0.75—2.15 0.38 89/958 (9.3) 8/159 (5.0) 1.05, 043—2.54 0.92
DM 144/435 (33.1) 19/71 (26.8) 0.88, 0.48—1.63 0.69 51/435 (11.7) 11/71 (15.5) 0.63, 0.25—1.56 0.33
Non-DM 200/704 (28.4) 14/154 (9.1) 1.64, 0.86—3.11 0.13 57/704 (8.1) 6/154 (3.9 0.89, 0.31—2.52 0.83
3VD/LMT 267/848 (31.5) 13/54 (24.1) 0.88, 0.44—1.77 0.72 83 (9.8) 9/54 (16.7) 0.30, 0.12—0.77 0.012
Non-3VD/LMT 77/291 (26.5) 20/171 (11.7) 138, 0.77—2.49 0.28 25/291 (8.6) 8/171 (4.7) 1.21, 0.45—3.29 0.70
CV death Revascularization
CABG PCI HR, 95%CI p CABG PCI HR, 95%CI p
ACS 27/181 (14.9) 9.66 (13.6) 0.32, 0.10—1.03 0.056 36/181 (19.9) 30/66 (45.5) 0.18, 0.08—0.40 <0.0001
Non-ACS 131/958 (24.8) 10/159 (6.3) 1.25, 0.58—2.68 0.58 179/958 (18.7) 77/159 (48.4) 0.20, 0.14—0.28 <0.0001
DM 66/435 (15.2) 13/71 (18.3) 0.55, 0.24—1.27 0.16 74/435 (17.0) 43/71 (60.6) 0.15, 0.09—0.28 <0.0001
Non-DM 92/704 (13.1) 6/154 (3.9) 1.62, 0.62—4.37 0.32 141/704 (20.0) 64/154 (41.6) 0.23, 0.16—0.35 <0.0001
3VD/LMT 125/848 (14.7) 9/54 (16.7) 0.61, 0.25—1.52 0.29 143 (16.7) 31 (57.4) 0.10, 0.06—0.17 <0.0001
Non-3VD/LMT 33 (11.3) 10 (5.9) 1.11, 0.48—2.60 0.82 72 (24.7) 76 (44.4) 0.30, 0.20—0.45 <0.0001
CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention; HR, hazard ratio; CI, conﬁdence interval; ACS, acute coronary syndrome; DM, diabetes mellitus; VD,
vessel disease; LMT left main trunk.
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Figure 4 Revascularization-free curves of patients after
PCI and CABG. Upper panel shows unadjusted cumula-
tive revascularization-free curve and lower panel shows
unadjusted cumulative revascularization-free curve.
Figure 5 Adjusted survival curves for patients who
underwent subsequent revascularization (n = 322). Pan-
els a, b, and c: survival curves from all-cause death,
cardiac death, and cardiovascular death, respectivelyRevascularization-free rate is signiﬁcantly lower in
patients after PCI than CABG. PCI, percutaneous coronary
intervention; CABG, coronary artery bypass graft.
patients were not randomly allocated as the revas-
cularization procedure was selected by doctors
after consideration of individual peri- and post-
procedural risk. Therefore, our ﬁndings might add
useful and clinically relevant information to the
data generated by the observational study using
the BARI registry cohort [10] and from other obser-
vational studies among populations of Japanese
patients [17—19]. In addition, we applied a propen-
sity analysis to adjust variables that would have
been related to the decision regarding the choice
of revascularization procedures. The ﬁndings of this
more sophisticated and advanced analysis might be
more relevant than those of previous studies.
(no signiﬁcant differences among groups). PCI, percu-
taneous coronary intervention; CABG, coronary artery
bypass graft; CV, cardiovascular.
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[CI vs. CABG
Our patients who underwent CABG had more
evere CAD, which strongly affects long-term mor-
ality. Nevertheless, long-term mortality rates did
ot signiﬁcantly differ after adjusting for base-
ine characteristics between patients undergoing
ABG with a higher estimated risk for mortality and
hose undergoing PCI. This is clinically important as
t indicates the reliability of the revascularization
trategy at that time.
We identiﬁed some crossover at the time of sub-
equent revascularization between patients who
nderwent initial PCI or CABG, and this crossover
ias might have affected the results. However,
ig. 5 shows no statistically signiﬁcant differences
mong the groups except for a lower mortality rate
n the group that initially underwent CABG and then
epeated CABG. This supports the primary ﬁndings
f the present study and is compatible with the
esults of a similar observational study in a western
atient population [20].
The low frequency of clinical events related to
oth the small number of subjects and the low
isk of the patients, resulted in limited statisti-
al power for detecting differences in outcome
etween the two groups. Since the present study
as observational in nature, even after adjustment
ncluding propensity analysis, other unknown
onfounders might have affected the outcomes.
nother limitation of the present study was that
ll of the patients underwent PCI comprising only
alloon angioplasty and CABG comprising only
n-pump bypass surgery. The application of stents
nd other supportive devices that are now widely
vailable, or of off-pump bypass surgery, might
ave generated quite different results. Further-
ore, arterial bypass was applied in only about 50%
f patients in the CABG group compared with an
pproximately 80% frequency of arterial grafts in
uch patients included in other recent comparisons
f PCI and CABG [21]. Other similar studies have
hown that patients who underwent PCI with stents
id not fare any better than, or had similar risk
o those who underwent contemporary CABG.
owever, the use of more recent stent devices
r drug-eluting stents (DES) might modulate the
uperiority of contemporary CABG [20,22—26].
urther investigation of oriental patient popula-
ions is required to clarify whether PCI with stents
ncluding DES is superior or equal to contemporary
ABG in terms of long-term mortality rates.onclusions
ong-term (>10 years) all-cause, cardiac, and car-
iovascular mortality rates did not differ between
[193
CI and CABG among a Japanese population of
atients. However, PCI was associated with a
igher risk for subsequent revascularization than
ABG.
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